Details for New Drug Application (NDA): 072263
✉ Email this page to a colleague
NDA 072263 describes MECLOFENAMATE SODIUM, which is a drug marketed by Am Therap, Ani Pharms, Barr, Chartwell Rx, Mylan, Par Pharm, Usl Pharma, Vitarine, and Watson Labs, and is included in eighteen NDAs. It is available from one supplier. Additional details are available on the MECLOFENAMATE SODIUM profile page.
The generic ingredient in MECLOFENAMATE SODIUM is meclofenamate sodium. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meclofenamate sodium profile page.
The generic ingredient in MECLOFENAMATE SODIUM is meclofenamate sodium. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meclofenamate sodium profile page.
Summary for 072263
| Tradename: | MECLOFENAMATE SODIUM |
| Applicant: | Chartwell Rx |
| Ingredient: | meclofenamate sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Nov 29, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
